GSK
Latest Trade
39.51USDChange
0.28(+0.71%)Volume
3,755,818Today's Range
-
39.5952 Week Range
-
42.40As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 39.23 |
|---|---|
Open | 39.50 |
Volume | 3,755,818 |
3M AVG Volume | 89.23 |
Today's High | 39.59 |
Today's Low | 39.38 |
52 Week High | 42.40 |
52 Week Low | 33.26 |
Shares Out (MIL) | 5,029.98 |
Market Cap (MIL) | 97,930.73 |
Forward P/E | 14.80 |
Dividend (Yield %) | 5.50 |
GSK Appoints Brian Mcnamara As CEO Designate Of New Consumer Healthcare Co
Sanofi: rolling reviews of COVID-19 recombinant vaccine to start soon in UK, Canada and Singapore
EU Drugs Regulator Starts Rolling Review Of Sanofi/GSK COVID-19 Vaccine
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Industry
Major Drugs
Contact Info
G S K House, 980 Great West Road
TW8 9GS
United Kingdom
+44.20.80475000
https://www.gsk.com/Executive Leadership
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Global Vaccines
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM) | 13.74 |
|---|---|
Price To Sales (TTM) | 2.20 |
Price To Book (MRQ) | 4.86 |
Price To Cash Flow (TTM) | 11.15 |
Total Debt To Equity (MRQ) | 176.38 |
LT Debt To Equity (MRQ) | 155.04 |
Return on Investment (TTM) | 11.51 |
Return on Equity (TTM) | 7.35 |
* GLAXOSMITHKLINE PLC - CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY
Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi and Britain's GlaxoSmithKline, the fifth shot currently under such a review.
* GSK-VIIV HEALTHCARE STUDY SHOWS NEW LONG-ACTING HIV REGIMEN CABENUVA CAN BE USED IN BROAD RANGE OF US HEALTHCARE PRACTICES, EVEN DURING COVID-19 Source text for Eikon: Further company coverage:
GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker as it bolsters its pipeline ahead of a split with its consumer healthcare venture.
* GLAXOSMITHKLINE PLC - GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS
Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising up to 400 million pounds ($552.76 million) by selling some land at the facility.
* GSK - UNVEILS PLAN FOR ONE OF EUROPE'S LARGEST LIFE SCIENCE CAMPUSES IN STEVENAGE
Italy approved the temporary distribution of a coronavirus antibody treatment by Britain's GlaxoSmithKline and U.S. company Vir Biotechnology, the health ministry said in a statement on Tuesday.
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
GlaxoSmithKline Plc and U.S. firm Alector Inc will together develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on Friday.
* GSK - NOTES LETTER ISSUED BY ELLIOTT ADVISORS (UK) LIMITED ("ELLIOTT") ON 1 JULY
Activist investor Elliott said GlaxoSmithKline should review its leadership and consider a sale of its consumer healthcare business as it confirmed on Thursday that it had taken a significant stake in the British pharmaceuticals group.
* BELIEVES GSK HAS SUBSTANTIAL VALUE CREATION OPPORTUNITY-45% UPSIDE IN ITS SHARE PRICE-AHEAD OF CONSUMER HEALTH SEPARATION AND GREATER BEYOND
French drugmaker Sanofi on Monday said it agreed to sell 16 mainly European consumer healthcare brands to private-equity owned Stada to streamline its product portfolio.
GlaxoSmithKline Plc has hired two banks to help advise it on listing its consumer unit next year and on defense against a potential activist campaign from Elliott Investment Management, Bloomberg News reported https://www.bloomberg.com/news/articles/2021-06-25/glaxosmithkline-said-to-tap-goldman-citi-for-spinoff...
Britain's FTSE 100 rose on Thursday, led by mining and healthcare-related stocks as the Bank of England kept its crisis-era monetary policy unchanged, while cruise operator Carnival fell after a quarterly loss of over $2 billion.
London's FTSE 100 marked time ahead of the Bank of England's rate decision on Thursday, while GlaxoSmithKline rose on plans to spin off its healthcare arm.
* GLAXOSMITHKLINE PLC - GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE
* GLAXOSMITHKLINE PLC - VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT
GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death among high-risk COVID-19 patients when given early in the disease.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.